ClinConnect ClinConnect Logo
Search / Trial NCT06836791

Topical 15% Trichloroacetic Acid Versus Silver Nitrate Cauterization in the Management of Idiopathic Childhood Epistaxis: A Prospective Double-Blinded, Randomized Clinical Trial

Launched by YOUSSEF ZAKI · Feb 19, 2025

Trial Information

Current as of June 14, 2025

Completed

Keywords

ClinConnect Summary

Epistaxis is a very distressing complaint in otorhinolaryngology that affects nearly 10-12% of the population worldwide . Epistaxis in children is even more common. Approximately half of the children had one or more episodes of epistaxis by the age of 10 .

The source of epistaxis may be anterior or posterior; in children, epistaxis is commonly anterior, originating mainly from the anterior part of the nasal septum called Little's area, in which a confluence of veins named Kiesselbach's plexus is the main area to blame . Anterior epistaxis is commonly related to local trauma, such as nose p...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All patients aged between 4 and 16 years at least once weekly in the last 4 weeks with visible anterior bleeding sources either unilateral or bilateral from Little's area were included in the study.
  • Exclusion Criteria:
  • All patients with documented coagulopathy, those with sinonasal or nasopharyngeal masses, those with active rhinosinusitis or severe allergic rhinitis or severe septal deviation

About Youssef Zaki

Youssef Zaki is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on improving patient outcomes, the organization collaborates with leading healthcare professionals and institutions to design and conduct rigorous clinical trials across various therapeutic areas. Youssef Zaki emphasizes ethical practices, regulatory compliance, and the integration of patient perspectives, ensuring that each study is conducted with the highest standards of quality and integrity. Through its strategic partnerships and commitment to scientific excellence, Youssef Zaki aims to contribute significantly to the development of safe and effective therapies.

Locations

Kafrelsheikh, , Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported